• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Biogen lifts outlook after strong Q2

July 25, 2017 By Sarah Faulkner

BiogenShares in Biogen (NSDQ:BIIB) rose today after the biopharmaceutical company met expectations on Wall Street with its second quarter results.

The Cambridge, Mass.-based company posted profits of $863 million, or $4.07 per share, on sales of $3.1 billion for the 3 months ended June 30, for bottom-line loss of -18% on sales growth of 6% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $5.04, ahead of consensus on The Street, where analysts were looking for sales of $2.81 billion.

“Biogen continued to perform well across multiple areas of our business. This quarter demonstrated our ability to advance and expand the pipeline, deliver strong commercial results, and build our senior management team,” CEO Michel Vounatsos said in prepared remarks. “Our market-leading MS portfolio continues to perform as we anticipated at the beginning of the year, as an increasing number of patients worldwide are benefiting from our therapies. Through Biogen’s efforts, patients are gaining access to Spinraza around the world for a disease that previously had no approved therapies. And, we have added exciting assets to our pipeline to drive future growth.”

“We are developing transformational therapies to address what we believe are becoming the world’s most significant unmet medical needs. Our mission is clear – the world needs a leader in neuroscience, and we aim to be that leader,” Vounatsos added.

Biogen said it expects to post adjusted EPS of $20.80 to $21.40 on sales of $11.5 billion to $11.8 billion for the full year. That’s up from what the company predicted in January, when it said it hoped to post adjusted EPS of $20.45 to $21.25 on sales of $11.1 billion to $11.4 billion.

BIIB shares were trading at $282.55 apiece today in afternoon activity, down -0.8%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Biogen Idec

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS